Skip to main content
Jianmin Pharmaceutical Group Co., Ltd. logo

Jianmin Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 600976 ISIN · CNE000001HB7 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,559 across all filing types
Latest filing 2024-04-19 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 600976

About Jianmin Pharmaceutical Group Co., Ltd.

https://www.whjm.com/

Jianmin Pharmaceutical Group Co., Ltd. is a specialized pharmaceutical enterprise with a heritage dating back to 1637. The company focuses on the research, development, and manufacturing of Traditional Chinese Medicine (TCM) and modern healthcare products. Its core portfolio emphasizes pediatric health, gynecological treatments, and chronic disease management. Key products include Longmu Zhuanggu Granules, recognized for supporting bone development and overall health in children. The group integrates traditional pharmacological wisdom with contemporary biotechnology and standardized production processes. Jianmin Group operates through a comprehensive value chain encompassing raw material sourcing, advanced manufacturing, and a distribution network. By leveraging its status as a time-honored brand, the company maintains a strong market position in the pediatric TCM segment while expanding its presence in general wellness and prescription drug markets.

Recent filings

Filing Released Lang Actions
健民集团2024年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2024 年第一季度报告' which translates to '2024 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on non-recurring gains and losses. The report explicitly states it is unaudited and covers the first quarter of 2024. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year clearly identifies this as an Interim / Quarterly Report. The document length is over 11,000 characters, indicating it is the full report, not just an announcement. Therefore, the appropriate classification is 'IR' for Interim / Quarterly Report. Q1 2024
2024-04-19 Chinese
健民集团关于硫酸特布他林雾化吸入用溶液获批上市的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from the company's board regarding the approval of a new drug (硫酸特布他林雾化吸入用溶液) for market launch by the national drug regulatory authority. It details the drug's specifications, approval status, market context, and potential impact on the company. The document is relatively short (1490 characters) and serves as a formal notification of a regulatory milestone rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or management analysis. It is not a report publication announcement since it is not announcing the release of a report but rather a regulatory approval event. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-04-15 Chinese
湖北得伟君尚律师事务所关于健民药业集团股份有限公司2023年年度股东大会的法律意见书
AGM Information Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2023 Annual General Meeting (AGM) of the company. It details the legality and validity of the meeting's convening, attendance, voting procedures, and results. It does not contain the actual annual report or financial statements but rather confirms the proper conduct and outcomes of the AGM. The document length is 2577 characters, which is relatively short and consistent with a legal opinion or meeting validation rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R), as it relates to materials shared or produced in connection with the AGM, specifically a legal opinion on the AGM proceedings.
2024-04-08 Chinese
健民集团2023年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a 2023 Annual General Meeting (AGM) resolution announcement for 健民药业集团股份有限公司. It details the date and location of the AGM, attendance, voting results on various proposals including the 2023 annual report, financial budget, profit distribution, and other corporate matters. The document is a formal announcement of the voting results and resolutions passed at the AGM, including legal opinions on the meeting's validity. The document length is 3685 characters, which is relatively short and consistent with an announcement rather than a full report. It does not contain the full annual report or detailed financial statements but rather the outcomes of the shareholder meeting votes. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-04-08 Chinese
健民集团2023年年度股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as materials for the 2023 Annual General Meeting (AGM) of 健民药业集团股份有限公司, dated April 8, 2024. It includes detailed agenda items for the AGM, such as the 2023 Board of Directors work report, Supervisory Board report, independent directors' reports, financial statements for 2023, profit distribution plan, and other proposals to be voted on by shareholders. The document also contains detailed reports from the Board of Directors, Supervisory Board, and independent directors, which are typical components of AGM materials. The presence of voting procedures and meeting logistics further confirms this is AGM presentation and materials. The document is comprehensive and not a brief announcement or a simple voting result declaration. Therefore, it fits the category of AGM Information (AGM-R).
2024-03-27 Chinese
健民集团关于2024年度对外担保额度预计的公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from the board of directors of 健民药业集团股份有限公司 regarding the expected external guarantee amount for the year 2024. It details the guarantee amounts, the companies involved, financial data of the subsidiaries, the approval process, and risk disclosures. The document is not a financial report, audit, or earnings release but rather a regulatory announcement about financing guarantees and related approvals. It does not contain comprehensive financial statements or detailed financial analysis but focuses on the guarantee limits and related corporate governance procedures. The document length is under 5,000 characters and is an announcement of a specific corporate action related to financing guarantees. This fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including guarantees and credit facilities.
2024-03-15 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.